|
31 Mar 2020 |
Spray-On Gene Therapy With RenovaCare SkinGun™ in New Study Underway at King’s College London
|
|
30 Mar 2020 |
Clinical outcomes of Mesoblast’s cell therapy in end-stage ischemic heart failure presented at American College of Cardiology virtual scientific sessions
|
|
30 Mar 2020 |
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
|
|
29 Mar 2020 |
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
|
|
27 Mar 2020 |
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
|
|
27 Mar 2020 |
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
|
|
26 Mar 2020 |
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
|
|
24 Mar 2020 |
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
|
|
24 Mar 2020 |
Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors
|
|
24 Mar 2020 |
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
|
|
24 Mar 2020 |
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
|
|
24 Mar 2020 |
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
|
|
23 Mar 2020 |
Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures
|
|
23 Mar 2020 |
Sorrento and Smartpharm to collaborate to develop novel gene-encoded antibody vaccine intended to protect against COVID-19
|
|
23 Mar 2020 |
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
|
|
20 Mar 2020 |
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
|
|
19 Mar 2020 |
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
|
|
19 Mar 2020 |
Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders
|
|
19 Mar 2020 |
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
|
|
18 Mar 2020 |
GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified Off-the-shelf Natural Killer Cells in 'Nature Scientific Reports'
|
|
18 Mar 2020 |
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
|
|
16 Mar 2020 |
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
|
|
13 Mar 2020 |
Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
|
|
13 Mar 2020 |
FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
|
|
13 Mar 2020 |
Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen’s First Clinical Product Candidate for Prevention of Recurrence of Clostridium Difficile Infection
|
